Palvella Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $45M
Latest Deal Amount
  • Investors
  • 10

Palvella Therapeutics General Information

Description

Developer of therapeutic agents intended to provide a cure for rare and ultra-rare diseases. The company's focus is in developing novel, disease-modifying therapy to treat pachyonychia congenita, an ultra-orphan, a chronically debilitating genetic disease, enabling patients to get treatment of rare diseases within reach.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 125 Strafford Avenue
  • Suite 360
  • Wayne, PA 19087
  • United States
+1 (484) 000-0000

Palvella Therapeutics Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Palvella Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 28-May-2020 $45M 000.00 00000 Completed Clinical Trials - Phase 3
5. Early Stage VC (Series B) 12-Aug-2019 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
4. Corporate 18-Dec-2018 0000 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A) 14-Jun-2018 00.000 00.000 000.00 Completed Clinical Trials - General
2. Grant $2.5M Completed Clinical Trials - General
1. Early Stage VC 01-Jun-2017 $2.5M $2.5M Completed Clinical Trials - General
To view Palvella Therapeutics’s complete valuation and funding history, request access »

Palvella Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 1,240,134 $0.000010 $1.64 $1.64 1x $1.64 6.56%
Series A-1 2,241,903 $0.000010 $1.31 $1.31 1x $1.31 11.85%
To view Palvella Therapeutics’s complete cap table history, request access »

Palvella Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic agents intended to provide a cure for rare and ultra-rare diseases. The company's focus is in d
Biotechnology
Wayne, PA
000.00
0000 0000-00-00
00000000000 000.00

00000000

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
0000 000000000
Saint Louis, MO
0 As of 0000
000.00
00000000000 000.00

000000 0

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
Cambridge, MA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Palvella Therapeutics Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunophotonics Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 00000000 0 Venture Capital-Backed Beijing, China 00000 00000000
You’re viewing 5 of 39 competitors. Get the full list »

Palvella Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Wesley Kaupinen Chief Executive Officer, President & Board Member
Kathleen McGowan Chief Financial Officer
Bradley Dickerson Chief Commercial Officer
Renee Mundy Ph.D Vice President, Portfolio Strategy
Braham Shroot Ph.D Chief Scientific Officer
To view Palvella Therapeutics’s complete executive team members history, request access »

Palvella Therapeutics Board Members (11)

Name Representing Role Since
Cory Freedland Ph.D Samsara BioCapital Board Member 000 0000
David Tierney MD Self Board Member 000 0000
Elaine Heron Ph.D Self Board Member 000 0000
George Jenkins Self Chairman 000 0000
John Doux MD Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Palvella Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adams Street Partners Fund of Funds Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
CAM Capital Asset Manager Minority 000 0000 000000 0
Nolan Capital Family Office Minority 000 0000 000000 0
Opaleye Management Other Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »